Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

Novartis

Status: Completed

Conditions: Chronic Iron Overload

Treatments: Other: Physician survey

Study type: Observational

Funder types: Industry

Identifiers

NCT06215287

CICL670A2429

EUPAS104950 (Other Identifier)

Details and patient eligibility

About

The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)

Enrollment: 400 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Physicians will be required to meet all of the following inclusion criteria:

• Must provide consent for participation
• Must spend ≥50% of time in direct patient care
• Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months.
• Have prescribed Exjade and/or generic deferasirox within the last 12 months.

Exclusion criteria

Physicians meeting the following criterion will not be eligible to take the survey:

• Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.

Trial design

400 participants in 1 patient group

Exjade Prescribers/HCP receiving Educational Materials

Description:

HCPs prescribing Exjade in the EU/EEA provided with Exjade Educational Materials

Treatment:

Other: Physician survey